These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21343553)

  • 1. Renal impairment in multiple myeloma: time is of the essence.
    Hutchison CA; Bridoux F
    J Clin Oncol; 2011 Apr; 29(11):e312-3; author reply e314. PubMed ID: 21343553
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum free light chains for monitoring multiple myeloma.
    Tate J; Mollee P; Gill D
    Br J Haematol; 2005 Feb; 128(3):405-6; author reply 406-7. PubMed ID: 15667546
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined analysis using extended renal reference range of serum free light chain ratio and serum protein electrophoresis improves the diagnostic accuracy of multiple myeloma in renal insufficiency.
    Park JW; Kim YK; Bae EH; Ma SK; Kim SW
    Clin Biochem; 2012 Jul; 45(10-11):740-4. PubMed ID: 22503879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
    Dimopoulos MA; Terpos E; Chanan-Khan A; Leung N; Ludwig H; Jagannath S; Niesvizky R; Giralt S; Fermand JP; Bladé J; Comenzo RL; Sezer O; Palumbo A; Harousseau JL; Richardson PG; Barlogie B; Anderson KC; Sonneveld P; Tosi P; Cavo M; Rajkumar SV; Durie BG; San Miguel J
    J Clin Oncol; 2010 Nov; 28(33):4976-84. PubMed ID: 20956629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Update in multiple myeloma: international criteria for treatment response and renal complications].
    Decaux O; Karras A
    Rev Med Interne; 2009 Dec; 30(12):1080-3. PubMed ID: 19833418
    [No Abstract]   [Full Text] [Related]  

  • 6. [5th International Symposium on clinical applications of serum free light chain analysis].
    Decaux O
    Rev Med Interne; 2009 Jan; 30(1):96-100. PubMed ID: 19054596
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progress in the management of multiple myeloma introduced by serum free light chain measurement].
    Shimazaki C
    Rinsho Ketsueki; 2010 Oct; 51(10):1491-8. PubMed ID: 20962483
    [No Abstract]   [Full Text] [Related]  

  • 9. [Difficulties evaluating hematological response in patients with multiple myeloma and dialysis - dependent renal impairment].
    Rekhtina IG; Mendeleeva LP; Soboleva NP
    Ter Arkh; 2019 Jul; 91(7):70-74. PubMed ID: 32598738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of serum free light chains predict renal recovery.
    Hutchison CA
    Ann Hematol; 2010 Jun; 89(6):627-8. PubMed ID: 19784650
    [No Abstract]   [Full Text] [Related]  

  • 11. [Renal failure].
    Arai T; Matsuzaki K
    Nihon Rinsho; 1995 Mar; 53(3):703-9. PubMed ID: 7699909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.
    Yadav P; Cockwell P; Cook M; Pinney J; Giles H; Aung YS; Cairns D; Owen RG; Davies FE; Jackson GH; Child JA; Morgan GJ; Drayson MT
    BMC Nephrol; 2018 Jul; 19(1):178. PubMed ID: 30012107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.
    Paiva B; Martinez-Lopez J; Vidriales MB; Mateos MV; Montalban MA; Fernandez-Redondo E; Alonso L; Oriol A; Teruel AI; de Paz R; Laraña JG; Bengoechea E; Martin A; Mediavilla JD; Palomera L; de Arriba F; Bladé J; Orfao A; Lahuerta JJ; San Miguel JF
    J Clin Oncol; 2011 Apr; 29(12):1627-33. PubMed ID: 21402611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma exchange after hematopoietic stem cell transplantation in multiple myeloma to reduce renal insufficiency.
    Sullivan K; Jagannath S; Mazumder A; Vesole DH
    Bone Marrow Transplant; 2008 Dec; 42(11):767. PubMed ID: 18695665
    [No Abstract]   [Full Text] [Related]  

  • 16. [Morphological and immunochemical features of nephropathies in multiple myeloma and severe renal failure].
    Rechtina IG; Golitsina EP; Varlamova EIu; Varshvskiĭ VA; Kireeva AA; Biriukova LS; Savchenko VG
    Ter Arkh; 2013; 85(3):80-5. PubMed ID: 23720848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.
    Hutchison CA; Cockwell P; Stringer S; Bradwell A; Cook M; Gertz MA; Dispenzieri A; Winters JL; Kumar S; Rajkumar SV; Kyle RA; Leung N
    J Am Soc Nephrol; 2011 Jun; 22(6):1129-36. PubMed ID: 21511832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving use of serum free light chain assays in haematology.
    Pratt G
    Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Light-chain removal by plasmapheresis in myeloma-associated renal failure.
    Cserti C; Haspel R; Stowell C; Dzik W
    Transfusion; 2007 Mar; 47(3):511-4. PubMed ID: 17319833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.